Abstract: The invention relates to novel compounds that are derivatives of 1,4-benzodiazepin-2-one, having the general formula I: and being limited to structural variants 1-6: on condition that: a) structures 1 (R1=Br, R4=F), 3 (R1=OCF3, R4=H), 5 (R1=NO2, R4=Cl) and 6 (R1=NO2, R4=F) have the following substituents R2 and R3: R2=H, CH2COCH3, CH2COOCH3, CH2CONHNH2; R3=OAlk, NHAr, where Alk=C2H5, C3H7, C4H9, (CH2)2OH, (CH2)2OCH3, R5=o-, m-, p-COCH3, Cl, F, Br, NO2, CF3; b) structure 2 (R1=Cl, R4=H) has the following substituents R2 and R3: if R2=H, then R3=OAlk, NHAr, where Alk=(CH2)2OCH3, R5=m-, p-COCH3, o-, m-, p-F, Br, CF3; ?if R2=CH2COCH3, CH2COOCH3, CH2CONHNH2, then R3=OAlk, NHAr, where Alk=C2H5, C3H7, C4H9, (CH2)2OH, (CH2)2OCH3, R5=o-, m-, p-COCH3, Cl, F, Br, NO2, CF3; c) structure 4 (R1=NO2, R4=H) has the following substituents R2 and R3: if R2=H, then R3=OAlk, NHAr, where Alk=(CH2)2OCH3, R5=o-, m-, p-COCH3, Cl, F, Br,

Abstract: The invention relates to food industry and medicine and describes the method of producing transformed plant cells, containing recombinant human alkaline phosphatase, and their use for maintaining the homeostasis of gastrointestinal tract as an agent, regulating gastrointestinal tract microflora and the immune system.

Abstract: The invention relates to novel compounds that are derivatives of 1,4-benzodiazepin-2-one, having the general formula I: and being limited to structural variants 1-6: on condition that: a) structures 1 (R1?Br, R4?F), 3 (R1?OCF3, R4?H), 5 (R1?NO2, R4?Cl) and 6 (R1?NO2, R4?F) have the following substituents R2 and R3: R2?H, CH2COCH3, CH2COOCH3, CH2CONHNH2; R3=OAlk, NHAr, where Alk=C2H5, C3H7, C4H9, (CH2)2OH, (CH2)2OCH3, R5=o-, m-, p-COCH3, Cl, F, Br, NO2, CF3; b) structure 2 (R1?Cl, R4?H) has the following substituents R2 and R3: if R2?H, then R3=OAlk, NHAr, where Alk=(CH2)2OCH3, R5=m-, p-COCH3, o-, m-, p-F, Br, CF3; if R2?CH2COCH3, CH2COOCH3, CH2CONHNH2, then R3=OAlk, NHAr, where Alk=C2H5, C3H7, C4H9, (CH2)2OH, (CH2)2OCH3, R5=o-, m-, p-COCH3, Cl, F, Br, NO2, CF3; c) structure 4 (R1?NO2, R4?H) has the following substituents R2 and R3: if R2?H, then R3=OAlk, NHAr, where Alk=(CH2)2OCH3, R5=o-, m

Abstract: The invention relates to pharmaceutical compositions based on a menthyl ester of indomethacin, which may be used as anti-inflammatory drugs to treat acute and chronic inflammatory diseases. The aforementioned pharmaceutical compositions have anti-inflammatory, analgesic and antipyretic action and don't have adverse ulcerogenic action in therapeutic doses. 1 independent claim, 7 tables, 1 figure, 13 examples.